Clinical Trial

Ledger Run Announces CEO Transition

Gary Lubin, Ledger Run's Founder and CEO, to retire and will continue on Board John Chinnici appointed as CEO for…

10 months ago

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) -- February 14, 2025 – IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing…

10 months ago

Hemostemix Provides Corporate Update

Calgary, Alberta--(Newsfile Corp. - February 13, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")…

10 months ago

PhaseV Launches Webinar Series on AI and Data-Driven Clinical Trial Optimization

BOSTON, Feb. 13, 2025 /PRNewswire/ -- PhaseV, a pioneer in software and machine learning (ML) for advanced clinical development optimization,…

11 months ago

Lindus Health and CDISC Collaborate on Innovative AI Initiative to Standardize Clinical Trial Data for Accelerated Research

NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials, has announced their…

11 months ago

Precision Cardiovascular Appoints Matthew I. Mace to Board of Directors, Bolstering Clinical and Regulatory Leadership

LONDON, Feb. 13, 2025 /PRNewswire/ -- Precision Cardiovascular (PCV), an innovator in next-generation cardiac health solutions, today announced the appointment…

11 months ago

Otolith Labs Announces Data Demonstrating Otolith Technology Effectiveness on Cybersickness from Virtual Reality in Exploratory Study

Original research article published by Frontiers, a top peer-reviewed scientific journal WASHINGTON, Feb. 13, 2025 /PRNewswire/ -- Otolith Labs, a…

11 months ago

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

– Filed for Regulatory Approval of Mitapivat (PYRUKYND®) for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia…

11 months ago

Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

– ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are…

11 months ago

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

--Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint…

11 months ago